Gorrissen Federspiel has advised Cross-Border Impact Ventures and EIFO, together with existing investors Novo Holdings and Athos, in connection with the EUR >30 million Series B investment in Bactolife.
Bactolife develops binding proteins to help maintain healthy microbiomes in humans and animals. The funding will provide Bactolife with sufficient capital to commercialize its binding proteins and execute human study program.
We congratulate the investors and Bactolife on the investment.
The core team consisted of Niels Bang, Caroline Boysen and Mads Walander.